Advancing nonclinical blood pressure assessment: Current practices and future directions in drug development.
Saved in:
| Title: | Advancing nonclinical blood pressure assessment: Current practices and future directions in drug development. |
|---|---|
| Authors: | Pugsley MK; Cytokinetics, Toxicology & Safety Pharmacology, South San Francisco, CA, USA., Bhatt S; Pfizer, Safety Sciences, Drug Safety Research and Development, Groton, CT, USA., Gottfridsson C; AstraZeneca, Cardiovascular Safety Center of Excellence, CMO, Patient Safety, Oncology R&D, Gothenburg, Sweden., Hoffmann P; Independent, Beaufort, SC, USA., Koshman YE; AbbVie, Safety Pharmacology, North Chicago, IL, USA., Norton K; Charles River Laboratories, Safety Pharmacology, Senneville, Quebec, Canada., O'Brien CE; Health and Environmental Sciences Institute, Washington, DC, USA., Pierson J; Health and Environmental Sciences Institute, Washington, DC, USA. Electronic address: jpierson@hesiglobal.org., Rossman EI; GSK, Safety Pharmacology, Collegeville, PA, 19426, USA., Taraboletti A; Health and Environmental Sciences Institute, Washington, DC, USA., Zabka TS; Genentech, Development Sciences-Safety Assessment, San Francisco, CA, USA., Foley CM; AbbVie, Safety Pharmacology, North Chicago, IL, USA. |
| Source: | Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2026 Aug; Vol. 169, pp. 106098. Date of Electronic Publication: 2026 Apr 14. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8214983 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-0295 (Electronic) Linking ISSN: 02732300 NLM ISO Abbreviation: Regul Toxicol Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
